Fluicell AB (FLUI) - Total Liabilities
Based on the latest financial reports, Fluicell AB (FLUI) has total liabilities worth Skr6.56 Million SEK (≈ $705.64K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Fluicell AB to evaluate the company's liquid asset resilience ratio.
Fluicell AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Fluicell AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Fluicell AB.
Fluicell AB Competitors by Total Liabilities
The table below lists competitors of Fluicell AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Austin Metals Ltd
AU:AYT
|
Australia | AU$201.35K |
|
C&C Group plc
LSE:CCR
|
UK | GBX812.48 Million |
|
NedSense Enterprises NV
AS:NEDSE
|
Netherlands | €416.00K |
|
Nicoccino Holding AB
ST:NICO
|
Sweden | Skr21.65 Million |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
India | Rs623.08 Million |
|
Belmont Resources Inc
V:BEA
|
Canada | CA$113.78K |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
USA | $7.60 Million |
|
Ambica Agarbathies & Aroma industries Limited
NSE:AMBICAAGAR
|
India | Rs1.32 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Fluicell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Fluicell AB (FLUI) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fluicell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fluicell AB (2014–2025)
The table below shows the annual total liabilities of Fluicell AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr7.57 Million ≈ $815.08K |
+20.72% |
| 2024-12-31 | Skr6.27 Million ≈ $675.18K |
-29.62% |
| 2023-12-31 | Skr8.91 Million ≈ $959.40K |
+7.15% |
| 2022-12-31 | Skr8.32 Million ≈ $895.36K |
+5.72% |
| 2021-12-31 | Skr7.87 Million ≈ $846.94K |
+47.60% |
| 2020-12-31 | Skr5.33 Million ≈ $573.81K |
-45.10% |
| 2019-12-31 | Skr9.71 Million ≈ $1.05 Million |
+273.54% |
| 2018-12-31 | Skr2.60 Million ≈ $279.80K |
+33.13% |
| 2017-12-31 | Skr1.95 Million ≈ $210.17K |
+109.10% |
| 2016-12-31 | Skr934.00K ≈ $100.51K |
-7.71% |
| 2015-12-31 | Skr1.01 Million ≈ $108.91K |
+108.76% |
| 2014-12-31 | Skr484.76K ≈ $52.17K |
-- |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more